Published in Oncogene on March 13, 2006
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer (2006) 3.52
Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res (2008) 3.05
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest (2010) 2.02
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res (2009) 1.48
Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci (2012) 1.44
Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther (2007) 1.42
Retracted Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis. J Ovarian Res (2013) 1.42
Drug resistance in cancer: an overview. Cancers (Basel) (2014) 1.39
Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin (2009) 1.39
Identification of functional modules that correlate with phenotypic difference: the influence of network topology. Genome Biol (2010) 1.25
High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines. Biochim Biophys Acta (2011) 1.13
Potentially functional variants of PLCE1 identified by GWASs contribute to gastric adenocarcinoma susceptibility in an eastern Chinese population. PLoS One (2012) 1.12
Spectra and kinetic studies of the compound I derivative of cytochrome P450 119. J Am Chem Soc (2008) 1.09
Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer (2007) 1.05
Aryl hydrocarbon receptor and lung cancer. Anticancer Res (2013) 0.99
Quantitative production of compound I from a cytochrome P450 enzyme at low temperatures. Kinetics, activation parameters, and kinetic isotope effects for oxidation of benzyl alcohol. J Am Chem Soc (2009) 0.98
Nuclear receptor CAR requires early growth response 1 to activate the human cytochrome P450 2B6 gene. J Biol Chem (2008) 0.96
Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet (2009) 0.95
Kinetics of oxidation of benzphetamine by compounds I of cytochrome P450 2B4 and its mutants. J Am Chem Soc (2009) 0.94
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget (2014) 0.92
Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic Biol Med (2007) 0.92
The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther (2014) 0.91
The antiapoptotic factor growth arrest and DNA-damage-inducible 45 beta regulates the nuclear receptor constitutive active/androstane receptor-mediated transcription. Drug Metab Dispos (2008) 0.90
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med (2008) 0.89
Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer. Pharmacogenet Genomics (2011) 0.89
Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist (2011) 0.89
Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies. Molecules (2012) 0.89
Early growth response 1 loops the CYP2B6 promoter for synergistic activation by the distal and proximal nuclear receptors CAR and HNF4alpha. FEBS Lett (2009) 0.88
Characteristic gene expression profiles in the progression from liver cirrhosis to carcinoma induced by diethylnitrosamine in a rat model. J Exp Clin Cancer Res (2009) 0.87
Far beyond the usual biomarkers in breast cancer: a review. J Cancer (2014) 0.87
Genetic variation in metabolic genes, occupational solvent exposure, and risk of non-hodgkin lymphoma. Am J Epidemiol (2011) 0.87
Comprehensive ultra-performance liquid chromatographic separation and mass spectrometric analysis of eicosanoid metabolites in human samples. J Chromatogr A (2014) 0.86
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol (2008) 0.85
MspI and Ile462Val polymorphisms in CYP1A1 and overall cancer risk: a meta-analysis. PLoS One (2013) 0.85
Necrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptions. Oncoscience (2014) 0.84
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int (2015) 0.84
Chronic heart failure: beta-blockers and pharmacogenetics. Eur J Clin Pharmacol (2008) 0.83
Cytochrome P450-activated prodrugs. Future Med Chem (2013) 0.82
MET inhibition in lung cancer. Transl Lung Cancer Res (2013) 0.82
Differential expression of cytochrome P450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma. PLoS One (2014) 0.81
Niche-dependent gene expression profile of intratumoral heterogeneous ovarian cancer stem cell populations. PLoS One (2013) 0.81
Smoking, the xenobiotic pathway, and clubfoot. Birth Defects Res A Clin Mol Teratol (2010) 0.80
Accurate DNA fragment sizing by capillary electrophoresis with laser-induced fluorescence array for detection of sequence specificity of DNA damage. Anal Chem (2008) 0.80
DMET™ (Drug Metabolism Enzymes and Transporters): a Pharmacogenomic platform for precision medicine. Oncotarget (2016) 0.80
Modulation of cytochrome P450 metabolism and transport across intestinal epithelial barrier by ginger biophenolics. PLoS One (2014) 0.80
Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus. Arch Med Sci (2011) 0.79
Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer. Cancer Res (2016) 0.78
Effects of schizonepetin on activity and mRNA expression of cytochrome p450 enzymes in rats. Int J Mol Sci (2012) 0.78
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation. Int J Exp Pathol (2015) 0.78
CYP1A1 rs1048943 and rs4646903 polymorphisms associated with laryngeal cancer susceptibility among Asian populations: a meta-analysis. J Cell Mol Med (2015) 0.77
Eureka-DMA: an easy-to-operate graphical user interface for fast comprehensive investigation and analysis of DNA microarray data. BMC Bioinformatics (2014) 0.77
Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile. Int J Clin Exp Med (2013) 0.77
Functional analysis of human cancer-associated genes and their association with the testes and epididymis. Oncol Lett (2013) 0.77
Protective Effects of Essential Oils as Natural Antioxidants against Hepatotoxicity Induced by Cyclophosphamide in Mice. PLoS One (2016) 0.77
The Effect of 5-Aminolevulinic Acid on Cytochrome P450-Mediated Prodrug Activation. PLoS One (2015) 0.77
Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities. Drug Des Devel Ther (2015) 0.77
Antiproliferative effect of gynura procumbens (lour.) Merr. Leaves etanolic extract on 7,12-dimethylbenz(a)antracene induced male rat liver. Adv Pharm Bull (2012) 0.77
Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Oncotarget (2016) 0.76
Discovery of tumor-specific irreversible inhibitors of stearoyl CoA desaturase. Nat Chem Biol (2016) 0.76
γH2AX and p53 responses in TK6 cells discriminate promutagens and nongenotoxicants in the presence of rat liver S9. Environ Mol Mutagen (2016) 0.76
Development of a High-Resolution Melting Analysis Method for CYP2C19*17 Genotyping in Healthy Volunteers. Avicenna J Med Biotechnol (2016) 0.76
Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-expression network analysis on breast cancer data. Sci Rep (2016) 0.76
Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients. Mol Cancer Ther (2015) 0.76
Distinct prognostic values of alcohol dehydrogenase mRNA expression in pancreatic adenocarcinoma. Onco Targets Ther (2017) 0.75
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. Oncotarget (2017) 0.75
Quercetin, a Flavonoid Antioxidant, Ameliorated Procarbazine-Induced Oxidative Damage to Murine Tissues. Antioxidants (Basel) (2015) 0.75
Tobacco habituated and non-habituated subjects exhibit different mutational spectrums in head and neck squamous cell carcinoma. 3 Biotech (2014) 0.75
Integrative Comparison of mRNA Expression Patterns in Breast Cancers from Caucasian and Asian Americans with Implications for Precision Medicine. Cancer Res (2016) 0.75
Adjuvant tamoxifen influences the lipid profile in breast cancer patients. Breast Care (Basel) (2014) 0.75
Genetic polymorphisms of human cytochrome P450 CYP1A1 in an Egyptian population and tobacco-induced lung cancer. Genes Environ (2017) 0.75
Transcriptomic dynamics of breast cancer progression in the MMTV-PyMT mouse model. BMC Genomics (2017) 0.75
Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia. J Adv Res (2013) 0.75
Autophagy and multidrug resistance in cancer. Chin J Cancer (2017) 0.75
Targeted CYP2E1 quantification and its correlation to currently acceptable clinical biochemical indices. J Biol Res (Thessalon) (2016) 0.75
Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC Med Genet (2012) 0.75
Tolfenamic acid suppresses cytochrome P450 2E1 expression in mouse liver. Integr Biol (Camb) (2012) 0.75
WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel. Sci Rep (2017) 0.75
Prevalence of the rs7903146C>T polymorphism in TCF7L2 gene for prediction of type 2 diabetes risk among Iranians of different ethnicities. Drug Des Devel Ther (2015) 0.75
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals (Basel) (2010) 0.75
Genetic polymorphisms of phase I metabolizing enzyme genes, their interaction with lifetime grilled and smoked meat intake, and breast cancer incidence. Ann Epidemiol (2016) 0.75
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clin Pharmacokinet (2017) 0.75
TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response. PLoS One (2015) 0.75
Genetic polymorphisms of CYP2D6 oxidation in patients with inflammatory bowel disease. Dig Dis Sci (2009) 0.75
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Invest New Drugs (2016) 0.75
Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. Clin Pharmacokinet (2017) 0.75
Inherent Oxidative Stress in Lewis Rat is Associated with Resistance to Toxoplasmosis. Infect Immun (2017) 0.75
Gene variants of CYP1A1 and CYP2D6 and the risk of childhood acute lymphoblastic leukaemia; outcome of a case control study from Kashmir, India. Mol Biol Res Commun (2017) 0.75
Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev (2001) 3.43
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology (1998) 2.19
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. Hepatology (1999) 1.81
Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol (1989) 1.78
Kupffer cell inactivation alleviates ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver. J Hepatol (2000) 1.69
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun (1999) 1.66
Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol. Gastroenterology (1997) 1.63
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51
Effects of short-term ethanol and nutrition on the hepatic microsomal monooxygenase system in a model utilizing total enteral nutrition in the rat. Alcohol Clin Exp Res (1991) 1.50
Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Hepatology (1996) 1.41
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther (1992) 1.41
Activation of protein kinase C by lipoxin A and other eicosanoids. Intracellular action of oxygenation products of arachidonic acid. Biochem Biophys Res Commun (1986) 1.37
In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun (1997) 1.34
Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol Pharmacol (1997) 1.26
A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol (1996) 1.26
Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos (2001) 1.23
Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett (1999) 1.23
Mechanisms of hydroxyl radical formation and ethanol oxidation by ethanol-inducible and other forms of rabbit liver microsomal cytochromes P-450. J Biol Chem (1984) 1.21
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. Proc Soc Exp Biol Med (2000) 1.21
PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics (1996) 1.17
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol (2001) 1.17
Ethanol-, fasting-, and acetone-inducible cytochromes P-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies. Biochemistry (1988) 1.16
Sodium periodate, sodium chlorite, and organic hydroperoxides as hydroxylating agents in hepatic microsomal steroid hydroxylation reactions catalyzed by cytochrome P-450. FEBS Lett (1975) 1.16
Medical chemistry: evaluation of active and problem-oriented teaching methods. Med Educ (1985) 1.15
The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol. Biochem Biophys Res Commun (2000) 1.13
Zonation of cytochrome P450 isozyme expression and induction in rat liver. Eur J Biochem (1992) 1.12
Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene (1999) 1.11
Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J (2012) 1.11
Effects of chronic ethanol on growth hormone secretion and hepatic cytochrome P450 isozymes of the rat. J Pharmacol Exp Ther (1993) 1.10
Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Commun (1999) 1.10
Cytochrome P450 CYP 2E1 induction during chronic alcohol exposure occurs by a two-step mechanism associated with blood alcohol concentrations in rats. J Pharmacol Exp Ther (1993) 1.08
Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer (1999) 1.08
Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis. Alcohol (1994) 1.08
Fish oil, alcohol, and liver pathology: role of cytochrome P450 2E1. Proc Soc Exp Biol Med (1994) 1.08
A stress-inducible rat liver endoplasmic reticulum protein, ERp29. Eur J Biochem (1998) 1.08
Ethanol and oxidative stress. Alcohol Clin Exp Res (2001) 1.07
Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther (2012) 1.07
Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther (2009) 1.06
Identification and characterization of a mitochondrial targeting signal in rat cytochrome P450 2E1 (CYP2E1). J Biol Chem (2000) 1.05
Effect of ethanol on cytochrome P450 2E1 (CYP2E1), lipid peroxidation, and serum protein adduct formation in relation to liver pathology pathogenesis. Exp Mol Pathol (1993) 1.05
Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology (1995) 1.05
Diet and risk of ethanol-induced hepatotoxicity: carbohydrate-fat relationships in rats. Toxicol Sci (1999) 1.04
Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett (1999) 1.04
Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics (1997) 1.04
Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun (2001) 1.04
Hormone- and substrate-regulated intracellular degradation of cytochrome P450 (2E1) involving MgATP-activated rapid proteolysis in the endoplasmic reticulum membranes. J Biol Chem (1992) 1.03
Lipid peroxidation, CYP2E1 and arachidonic acid metabolism in alcoholic liver disease in rats. J Nutr (1997) 1.03
Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem Biophys Res Commun (2001) 1.02
Zonated expression of cytokines in rat liver: effect of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole. Hepatology (1998) 1.02
Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab Rev (1999) 1.01
Purification and characterization of cytochrome P-450meg. J Biol Chem (1979) 1.01
A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol (1997) 1.01
Characterization of a cytochrome P-450-dependent steroid hydroxylase system present in Bacillus megaterium. J Biol Chem (1976) 1.00
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics (1996) 0.99
Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics (1993) 0.99
Regulation and properties of a sex-specific hydroxylase system in female rat liver microsomes active on steroid sulfates. I. General characteristics. J Biol Chem (1974) 0.98
Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane. J Biol Chem (2000) 0.98
Sodium periodate, sodium chloride, organic hydroperoxides, and H2O2 as hydroxylating agents in steroid hydroxylation reactions catalyzed by partially purified cytochrome P-450. Biochem Biophys Res Commun (1975) 0.98
Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures. Biochem Biophys Res Commun (1988) 0.98
Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system. Neuroscience (1990) 0.97
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J (2007) 0.97
Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. Mol Pharmacol (2003) 0.97
Protein kinase C-dependent phosphorylation of profilin is specifically stimulated by phosphatidylinositol bisphosphate (PIP2). Biochem Biophys Res Commun (1988) 0.96
CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos (2001) 0.96
Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett (1998) 0.95
Incorporation of purified components of the rabbit liver microsomal hydroxylase system into phospholipid vesicles. Biochim Biophys Acta (1980) 0.94
Structural and functional characterization of the 5'-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun (1999) 0.94
Hydroxyl radical-mediated, cytochrome P-450-dependent metabolic activation of benzene in microsomes and reconstituted enzyme systems from rabbit liver. J Biol Chem (1983) 0.94
Thioredoxin fold as homodimerization module in the putative chaperone ERp29: NMR structures of the domains and experimental model of the 51 kDa dimer. Structure (2001) 0.94
Effects of diet and ethanol on the expression and localization of cytochromes P450 2E1 and P450 2C7 in the colon of male rats. Biochem Pharmacol (1996) 0.93
H2O2 activates CD11b/CD18-dependent cell adhesion. Biochem Biophys Res Commun (1988) 0.93
Carbon tetrachloride-induced lipid peroxidation dependent on an ethanol-inducible form of rabbit liver microsomal cytochrome P-450. FEBS Lett (1985) 0.93
S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics (1996) 0.93
Membrane charge as effector of cytochrome P-450LM2 catalyzed reactions in reconstituted liposomes. Biochemistry (1981) 0.92
Hydroxyethyl radicals in ethanol hepatotoxicity. Front Biosci (1999) 0.92
Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol (1997) 0.92
Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. Free Radic Biol Med (1991) 0.91
Specific metabolic pathways of steroid sulfates in human liver microsomes. J Clin Endocrinol Metab (1976) 0.91
Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury. Mol Pharmacol (1996) 0.91
The ubiquitin-proteasome 26s pathway in liver cell protein turnover: effect of ethanol and drugs. Alcohol Clin Exp Res (2001) 0.91
Substrate-, hormone-, and cAMP-regulated cytochrome P450 degradation. Proc Natl Acad Sci U S A (1990) 0.91
Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol (1991) 0.91
Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun (2001) 0.91
Autoantibodies against cytochromes P-4502E1 and P-4503A in alcoholics. Mol Pharmacol (1999) 0.91
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics (1999) 0.91
Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics (2001) 0.90
Acetone-regulated synthesis and degradation of cytochrome P450E1 and cytochrome P4502B1 in rat liver [corrected]. Eur J Biochem (1991) 0.90
Enzyme-specific transport of rat liver cytochrome P450 to the Golgi apparatus. Arch Biochem Biophys (1996) 0.90
Expression and distribution of cytochrome P450 enzymes in male rat kidney: effects of ethanol, acetone and dietary conditions. Biochem Pharmacol (1998) 0.89
Reductive metabolism and protein binding of chromium(VI) by P450 protein enzymes. Carcinogenesis (1991) 0.89
Cyclic expression of class I alcohol dehydrogenase in male rats treated with ethanol. Biochem Biophys Res Commun (2000) 0.89
Cytochrome P-450 and oxygen toxicity. Oxygen-dependent induction of ethanol-inducible cytochrome P-450 (IIE1) in rat liver and lung. Biochemistry (1989) 0.89
A soluble NH(2)-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria(1). FEBS Lett (1999) 0.89